In an exciting development in the world of biotechnology, CGT Global and Octomera have entered into a groundbreaking agreement aimed at expanding cell and gene therapy development and patient access across the United States. This partnership promises to revolutionize the landscape of medical care, bringing advanced therapies closer to patients than ever before.
Orgenesis Inc. (NASDAQ: ORGS), a global biotech company, is spearheading this initiative through its subsidiary, Octomera. The collaboration between Octomera and CGT Global, a biomedical company dedicated to advancing medical science and patient therapies, is set to leverage CGT Global’s extensive network of CGT Clinics and healthcare partnerships to commercialize CGTs in California and various other locations in the United States.
“Together with CGT Global, we will leverage their existing expertise, healthcare network, and clinics to rapidly expand the support offering for point of care and advanced therapeutic production services. We are thrilled about the potential to overcome challenges with accessible end-to-end blood collection and cell production.”
Vered Caplan, CEO of Octomera and Orgenesis
“At CGT Global, we have been creating a network of hospitals and CGT Clinics that reach far and wide with the goal of ensuring that all patients, regardless of location and financial status, can have access to the best medicines on the market”
Cate Spears, CEO and Founder of CGT Global
A BRIGHT FUTURE AHEAD
This collaboration comes at a pivotal moment when the world is increasingly relying on advanced therapies to address complex medical conditions. With the versatility of OMPULs and the commitment of both CGT Global and Octomera, there are exciting times ahead for this partnership. It promises to be a game-changer in the field of biotechnology and could lead to more accessible and efficient healthcare solutions for patients worldwide.
To read the full press release, click HERE.
For those interested in learning how you can partner with CGT Global, click HERE, and we will contact you directly.